SCHEMBL925888

SCHEMBL925888

Fc1cccc(Nc2ncnc3sc4ccccc4c23)c1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 4/20 0.60
EGFR P00533 7/20 0.59
ABCG2 Q9UNQ0 1/20 0.59
MAPK1 P28482 3/20 0.58
HTT P42858 3/20 0.58
MAPT P10636 3/20 0.58
LMNA P02545 1/20 0.58
RAF1 P04049 1/20 0.58
RAB9A P51151 2/20 0.58
ABL1 P00519 1/20 0.50
ABL2 P42684 1/20 0.50
KDM4E B2RXH2 1/20 0.46
NPC1 O15118 1/20 0.46
FGFR1 P11362 1/20 0.46
GRM1 Q13255 1/20 0.46
HPGD P15428 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL924526 0.85 MKNK1 (0.60) MKNK1EGFRHTTMAPTABL1
SCHEMBL923953 0.85 EGFR (0.67) EGFRABCG2
SCHEMBL924677 0.77 PDE5A (0.43) MKNK1EGFRABCG2MAPK1HTT
SCHEMBL923247 0.75 MKNK1 (1.00) MKNK1EGFRMAPK1HTTMAPT
SCHEMBL668559 0.74 EGFR (1.00) EGFRABCG2HTTABL1
SCHEMBL16247566 0.68 IDO1 (0.71) RAB9AKDM4ENPC1
SCHEMBL29058751 0.68 EGFR (0.71) MKNK1EGFRABCG2MAPK1HTT
SCHEMBL30395473 0.68 EGFR (0.71) MKNK1EGFRABCG2MAPK1HTT
SCHEMBL10960192 0.67 EGFR (0.63) MKNK1EGFRABCG2MAPK1HTT
SCHEMBL4741057 0.67 TTBK1 (0.71) MKNK1EGFRABCG2MAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8802849-B2 Tricyclic benzo[4,5]thieno-[2,3-d]pyrimidine-4-yl-amin derivatives, their salts, process for producing the compounds and their pharmaceutical use VICHEM CHEMIE KUTATÓ KFT. (HU) 2014-08-12 US claimed
US-20110015214-A1 TRICYCLIC BENZO[4,5]THIENO-[2,3-D]PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE VICHEM CHEMIE KUTATO KFT. (HU) 2011-01-20 US claimed
EP-2257554-A1 TRICYCLIC BENZOÝ4,5¨THIENO-Ý2,3-D¨PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE Vichem Chemie Kutató KFT (HU) 2010-12-08 EP claimed
WO-2009104026-A1 TRICYCLIC BENZO[4,5]THIENO-[2,3-D]PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE VICHEM CHEMIE KUTATÓ KFT (HU) 2009-08-27 WO claimed
US-8802849-B2 Tricyclic benzo[4,5]thieno-[2,3-d]pyrimidine-4-yl-amin derivatives, their salts, process for producing the compounds and their pharmaceutical use VICHEM CHEMIE KUTATÓ KFT. (HU) 2014-08-12 US disclosed
US-20110015214-A1 TRICYCLIC BENZO[4,5]THIENO-[2,3-D]PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE VICHEM CHEMIE KUTATO KFT. (HU) 2011-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015214-A1 TRICYCLIC BENZO[4,5]THIENO-[2,3-D]PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE TYMS, TYMP, DPYD MKNK1 2917/4885EGFR 2403/4885ABCG2 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.